Teduglutide Reduces Need for Parenteral Support Among Patients With Short Bowel Syndrome With Intestinal Failure

Article ID	Journal	Published Year	Pages	File Type
3293858	Gastroenterology	2012	12 Pages	PDF

Abstract

Twenty-four weeks of teduglutide treatment was generally well tolerated in patients with SBS-IF. Treatment with teduglutide reduced volumes and numbers of days of parenteral support for patients with SBS-IF; ClinicalTrials.gov Number, NCT00798967.

Keywords

SBS GLP-2 FCE TEAE Gastrointestinal disorder Therapy Short bowel syndrome Intestinal failure adverse event treatment-emergent adverse event glucagon-like peptide 2 Clinical trial

Related Topics

Health Sciences Medicine and Dentistry Gastroenterology

Preview

Teduglutide Reduces Need for Parenteral Support Among Patients With Short Bowel Syndrome With Intestinal Failure

Authors

Palle B. Jeppesen, Marek Pertkiewicz, Bernard Messing, Kishore Iyer, Douglas L. Seidner, Stephen J.D. O'keefe, Alastair Forbes, Hartmut Heinze, Bo Joelsson,